GSK plc 6-K, filed Nov 3, 2020
GSK plc (GSK)
6-K
2020-11-03
For: 2020-11-03
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on November 3, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: GlaxoSmithKline plc, 3 November 2020, London
UK
GSK sets new environmental goals of net zero impact on climate and
net positive impact on nature by 2030
Increasing scientific evidence[1] demonstrates
that climate change and nature loss are impacting the world and
human health in many ways, including: extreme heat contributing to
deaths from diseases; increased spread of infectious diseases and
air pollution exacerbating respiratory
diseases.
Today, GSK has announced ambitious new environmental sustainability
goals in both climate and nature, aiming to have a net zero impact
on climate and a net positive impact on nature by
2030.
The new goals form part of GSK's Trust priority and ESG approach,
which support the company's aim to create long-term value for
shareholders and meet the needs of society. Over the next decade,
GSK will invest in measures to reduce its environmental impact, in
restoration programmes to balance the remaining impact that the
company cannot reduce and aim to put back into nature more than the
company takes out.
Underpinning these goals, the company has set new targets across
its different businesses, including: 100% renewable electricity
usage and good water stewardship at all GSK sites; 100% of
materials sustainably sourced and deforestation free and
transitioning to 100% usage of electric vehicles by GSK sales
representatives worldwide. More
information on the goals and the targets are available on
gsk.com.
Emma Walmsley, Chief Executive Officer, GSK,
said, "As a global healthcare
company, we want to play our full part in protecting and restoring
the planet's health, in order to protect and improve people's
health. Improving the environmental sustainability of our business
also makes us more resilient, protecting our operations, so we can
deliver the products that patients and consumers rely
on.
"As part of our Trust priority and ESG commitments, we are
announcing a new level of ambition on environmental sustainability,
with the twin goals of ensuring the new GSK has a net zero impact
on climate and a net positive impact on nature by
2030.
"All of us working at GSK are very motivated by the challenge of
delivering these new goals. Meeting these goals will require
working closely with others, including our suppliers, customers,
consumers and patients, and we are grateful for their
support."
The new goals apply principally to GSK's Biopharma business and
portfolio. The company's Consumer Healthcare business will also
contribute towards these goals through delivery of its own targets,
whilst it is part of GSK. Post separation, the new Consumer
Health company will be a world-leading business and its new targets
reflect this, representing a significant new level of ambition, to
drive positive environmental change and help improve everyday
health.
GSK has long been committed to reducing its environmental impact
and was one of the first pharmaceutical companies to set ambitious
environment targets in 2010. Since then, across its operations GSK
has reduced carbon emissions by 34%, waste to landfill by 78% and
total water use by 31% (2019 figures).
The Science Based Targets Initiative has accredited that GSK's new
carbon targets align to a 1.5° pathway - in line with the most
ambitious goal of the Paris Agreement. The company will align
to the Science Based Targets Network approach to measure its impact
on nature and will seek to accredit its nature target when the
methodology is finalised.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kristen
Neese
|
+1 804
217 8147
|
(Philadelphia)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
Danielle
Morris
|
+44 (0)
20 8047 7562
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk Factors" in the company's Annual Report on Form 20-F for 2019
and as set out in GSK's "Principal risks and uncertainties" section
of the Q3 Results and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford, Middlesex
TW8
9GS
[1] The
2019 report of
the Lancet Countdown
on health and climate change ensuring that the health of a child
born today is not defined by a changing climate
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
03, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|